%0 Journal Article
%T A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers.
%A Liu K
%A Li M
%A Li Y
%A Li Y
%A Chen Z
%A Tang Y
%A Yang M
%A Deng G
%A Liu H
%J Mol Cancer
%V 23
%N 1
%D 2024 03 23
%M 38519953
%F 41.444
%R 10.1186/s12943-024-01963-7
%X While strategies such as chemotherapy and immunotherapy have become the first-line standard therapies for patients with advanced or metastatic cancer, acquired resistance is still inevitable in most cases. The introduction of antibody‒drug conjugates (ADCs) provides a novel alternative. ADCs are a new class of anticancer drugs comprising the coupling of antitumor mAbs with cytotoxic drugs. Compared with chemotherapeutic drugs, ADCs have the advantages of good tolerance, accurate target recognition, and small effects on noncancerous cells. ADCs occupy an increasingly important position in the therapeutic field. Currently, there are 13 Food and Drug Administration (FDA)‒approved ADCs and more than 100 ADC drugs at different stages of clinical trials. This review briefly describes the efficacy and safety of FDA-approved ADCs, and discusses the related problems and challenges to provide a reference for clinical work.